MediWound Ltd. (NASDAQ:MDWD) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of MediWound Ltd. (NASDAQ:MDWD) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.00.

A number of research analysts have issued reports on MDWD shares. Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. TD Cowen reiterated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners reissued a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Finally, Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.20% of the company’s stock.

MediWound Stock Up 6.0%

Shares of MDWD opened at $14.20 on Thursday. MediWound has a 12-month low of $11.80 and a 12-month high of $19.70. The firm has a market capitalization of $182.47 million, a PE ratio of -7.89 and a beta of 0.07. The stock’s fifty day simple moving average is $13.09 and its 200-day simple moving average is $15.18.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. Analysts anticipate that MediWound will post -2.37 EPS for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.